W. Boehncke and M. P. Schön, Psoriasis. Lancet, vol.386, pp.983-994, 2015.

M. A. Lowes, M. Suárez-fariñas, and J. G. Krueger, Immunology of psoriasis, Annu. Rev. Immunol, vol.32, pp.227-255, 2014.

R. Sabat, S. Philipp, C. Höflich, S. Kreutzer, E. Wallace et al., Immunopathogenesis of psoriasis, Exp. Dermatol, vol.16, pp.779-798, 2007.

T. Kopp, E. Riedl, C. Bangert, E. P. Bowman, E. Greisenegger et al., Clinical improvement in psoriasis with specific targeting of interleukin-23, Nature, vol.521, pp.222-226, 2015.

K. B. Gordon, A. Blauvelt, K. A. Papp, R. G. Langley, T. Luger et al.,

, Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis, N. Engl. J. Med, vol.375, issue.2, pp.345-356, 2016.

R. G. Langley, B. E. Elewski, M. Lebwohl, K. Reich, C. E. Griffiths et al., Secukinumab in plaque psoriasisresults of two phase 3 trials, N. Engl. J. Med, vol.371, pp.326-338, 2014.

M. Lebwohl, B. Strober, A. Menter, K. Gordon, J. Weglowska et al., Phase 3 studies comparing brodalumab with ustekinumab in psoriasis, N. Engl. J. Med, vol.373, pp.1318-1328, 2015.

K. Wolk, S. Kunz, E. Witte, M. Friedrich, K. Asadullah et al., IL-22 increases the innate immunity of tissues, Immunity, vol.21, pp.241-254, 2004.

S. Rutz, X. Wang, and W. Ouyang, The IL-20 subfamily of cytokinesfrom host defence to tissue homeostasis, Nat. Rev. Immunol, vol.14, pp.783-795, 2014.

R. Sabat, W. Ouyang, and K. Wolk, Therapeutic opportunities of the IL-22-IL-22R1 system, Nat. Rev. Drug Discov, vol.13, pp.21-38, 2014.

J. A. Dudakov, A. M. Hanash, M. R. Van-den, and . Brink, Interleukin-22: immunobiology and pathology, Annu. Rev. Immunol, vol.33, pp.747-785, 2015.

K. Boniface, F. Bernard, M. Garcia, A. L. Gurney, J. Lecron et al., IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes, J. Immunol, vol.174, pp.3695-3702, 2005.
URL : https://hal.archives-ouvertes.fr/hal-01705207

K. Wolk, E. Witte, E. Wallace, W. Döcke, S. Kunz et al., IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis, Eur. J. Immunol, vol.36, pp.1309-1323, 2006.

K. Wolk, H. S. Haugen, W. Xu, E. Witte, K. Waggie et al., IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not, J. Mol. Med. (Berl.), vol.87, pp.523-536, 2009.

G. K. Perera, C. Ainali, E. Semenova, C. Hundhausen, G. Barinaga et al., Integrative biology approach identifies cytokine targeting strategies for psoriasis, Sci. Transl. Med, vol.6, pp.223-245, 2014.

H. Ma, S. Liang, J. Li, L. Napierata, T. Brown et al., IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation, J. Clin. Invest, vol.118, pp.597-607, 2008.

L. Dumoutier, D. Lejeune, D. Colau, and J. C. Renauld, Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22, J. Immunol, vol.166, pp.7090-7095, 2001.

S. V. Kotenko, L. S. Izotova, O. V. Mirochnitchenko, E. Esterova, H. Dickensheets et al., Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity, J. Immunol, vol.166, pp.7096-7103, 2001.

W. Xu, S. R. Presnell, J. Parrish-novak, W. Kindsvogel, S. Jaspers et al., A soluble class II cytokine receptor, IL-22RA2, is a naturally occurring IL-22 antagonist, Proc. Natl. Acad. Sci. USA, vol.98, pp.9511-9516, 2001.

B. H. Gruenberg, A. Schoenemeyer, B. Weiss, L. Toschi, S. Kunz et al., A novel, soluble homologue of the human IL-10 receptor with preferential expression in placenta, Genes Immun, vol.2, pp.329-334, 2001.

J. C. Martin, G. Bériou, M. Heslan, C. Chauvin, L. Utriainen et al., Interleukin-22 binding protein (IL-22BP) is constitutively expressed by a subset of conventional dendritic cells and is strongly induced by retinoic acid, Mucosal Immunol, vol.7, pp.101-113, 2014.

J. C. Martin, G. Bériou, M. Heslan, C. Bossard, A. Jarry et al., IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis, Mucosal Immunol, vol.9, pp.539-549, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02150949

S. Huber, N. Gagliani, L. A. Zenewicz, F. J. Huber, L. Bosurgi et al., IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine, Nature, vol.491, pp.259-263, 2012.

K. Wolk, H. Mitsui, K. Witte, S. Gellrich, N. Gulati et al., Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function, Clin. Cancer Res, vol.20, pp.5507-5516, 2014.

K. Wolk, K. Witte, E. Witte, M. Raftery, G. Kokolakis et al., IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis, Sci. Transl. Med, vol.5, pp.204-129, 2013.

K. Wolk, K. Warszawska, C. Hoeflich, E. Witte, S. Schneider-burrus et al., Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa, J. Immunol, vol.186, pp.1228-1239, 2011.

L. Drujont, A. Lemoine, A. Moreau, G. Bienvenu, M. Lancien et al., RORgt+ cells selectively express redundant cation channels linked to the Golgi apparatus, Sci. Rep, vol.6, p.23682, 2016.

M. M. Lemaire, A. Vanhaudenarde, Y. Nizet, L. Dumoutier, and J. Renauld, Induction of autoantibodies against mouse soluble proteins after immunization with living cells presenting the autoantigen at the cell surface in fusion with a human type 2 transmembrane protein, J. Immunol. Methods, vol.367, pp.56-62, 2011.

K. Boniface, E. Guignouard, N. Pedretti, M. Garcia, A. Delwail et al., A role for T cell-derived interleukin 22 in psoriatic skin inflammation, Clin. Exp. Immunol, vol.150, pp.407-415, 2007.
URL : https://hal.archives-ouvertes.fr/hal-01705160

B. Flutter and F. O. Nestle, TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis, Eur. J. Immunol, vol.43, pp.3138-3146, 2013.

L. Van-der-fits, S. Mourits, J. S. Voerman, M. Kant, L. Boon et al., Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis, J. Immunol, vol.182, pp.5836-5845, 2009.

A. B. Van-belle, M. De-heusch, M. M. Lemaire, E. Hendrickx, G. Warnier et al., IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice, J. Immunol, vol.188, pp.462-469, 2012.

T. Zelante, R. G. Iannitti, C. Cunha, A. De-luca, G. Giovannini et al., Tryptophan catabolites from microbiota engage aryl hydrocarbon receptor and balance mucosal reactivity via interleukin-22, Immunity, vol.39, pp.372-385, 2013.

S. J. Aujla, Y. R. Chan, M. Zheng, M. Fei, D. J. Askew et al., IL-22 mediates mucosal host defense against gram-negative bacterial pneumonia, Nat. Med, vol.14, pp.275-281, 2008.

K. Wolk, E. Witte, K. Warszawska, G. Schulze-tanzil, K. Witte et al., The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis, Eur. J. Immunol, vol.39, pp.3570-3581, 2009.

Y. Carrier, H. Ma, H. E. Ramon, L. Napierata, C. Small et al., Interregulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis, J. Invest. Dermatol, vol.131, pp.2428-2437, 2011.

H. Blumberg, D. Conklin, W. F. Xu, A. Grossmann, T. Brender et al., Interleukin 20: discovery, receptor identification, and role in epidermal function, Cell, vol.104, pp.9-19, 2001.

L. Tortola, E. Rosenwald, B. Abel, H. Blumberg, M. Schäfer et al., Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk, J. Clin. Invest, vol.122, pp.3965-3976, 2012.

S. C. Liang, X. Tan, D. P. Luxenberg, R. Karim, K. Dunussi-joannopoulos et al., Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides, J. Exp. Med, vol.203, pp.2271-2279, 2006.

J. Rømer, E. Hasselager, P. L. Nørby, T. Steiniche, J. T. Clausen et al., Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol, J. Invest. Dermatol, vol.121, pp.1306-1311, 2003.

S. Kunz, K. Wolk, E. Witte, K. Witte, W. Doecke et al., Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs, Exp. Dermatol, vol.15, pp.991-1004, 2006.

S. Kumari, M. C. Bonnet, M. H. Ulvmar, K. Wolk, N. Karagianni et al., Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice, Immunity, vol.39, pp.899-911, 2013.

S. M. Sa, P. A. Valdez, J. Wu, K. Jung, F. Zhong et al., The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis, J. Immunol, vol.178, pp.2229-2240, 2007.

M. Tohyama, Y. Hanakawa, Y. Shirakata, X. Dai, L. Yang et al., IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression, Eur. J. Immunol, vol.39, pp.2779-2788, 2009.

S. Kagami, H. L. Rizzo, J. J. Lee, Y. Koguchi, and A. Blauvelt, Circulating Th17, Th22, and Th1 cells are increased in psoriasis, J. Invest. Dermatol, vol.130, pp.1373-1383, 2010.

D. D. Patel and V. K. Kuchroo, Th17 cell pathway in human immunity: lessons from genetics and therapeutic interventions, Immunity, vol.43, pp.1040-1051, 2015.

H. Lindahl, E. Martini, S. Brauner, P. Nikamo, I. Gallais et al., IL-22 binding protein regulates murine skin inflammation, Exp. Dermatol, 2016.

B. Weiss, K. Wolk, B. H. Gr?-unberg, H. Volk, W. Sterry et al., Cloning of murine IL-22 receptor alpha 2 and comparison with its human counterpart, Genes Immun, vol.5, pp.330-336, 2004.